ଇଷ୍ଟ୍ରାଡେଫାଇଲିନ

ଇଷ୍ଟ୍ରାଡେଫାଇଲିନ
Clinical data
Trade names	Nourianz, Nouryant
Synonyms	KW-6002
AHFS/Drugs.com	monograph
data	US DailyMed: Istradefylline;
Routes of; administration	By mouth
Legal status
Legal status	US: ℞-only ;
Pharmacokinetic data
Protein binding	98%
Metabolism	Mainly CYP1A1, CYP3A4, and CYP3A5
Elimination half-life	64–69 hrs
Excretion	68% faeces, 18% urine
Identifiers
	IUPAC name 8-[(E)-2-(3,4-dimethoxyphenyl)vinyl]-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione;
ECHA InfoCard	100.230.117
Chemical and physical data
Formula	C20H24N4O4
Molar mass	୩୮୪.୪୪ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C2N(c1nc(n(c1C(=O)N2CC)C)\C=C\c3ccc(OC)c(OC)c3)CC;
	InChI InChI=1S/C20H24N4O4/c1-6-23-18-17(19(25)24(7-2)20(23)26)22(3)16(21-18)11-9-13-8-10-14(27-4)15(12-13)28-5/h8-12H,6-7H2,1-5H3/b11-9+ ; Key:IQVRBWUUXZMOPW-PKNBQFBNSA-N ;
(verify)

ଇଷ୍ଟ୍ରାଡେଫାଇଲିନ (ଇଂରାଜୀ ଭାଷାରେ Istradefylline), ନ୍ୟୁରିୟାନ୍ଜ୍ ଏହାର ବିକ୍ରୟ ନାମ, ହେଉଛି ଏକ ଔଷଧ ଯାହା ପାର୍କିନ୍‌ସନ୍ ରୋଗର (ପିଡି) “ଅଫ୍” ଏପିସୋଡ୍/ ବୃତ୍ତାନ୍ତ ପାଇଁ ଲେଭୋଡୋପା/କାର୍ବିଡୋପା ସହିତ ବ୍ୟବହୃତ ହୁଏ ।^[୩] ^[୪] ଏକ "ଅଫ୍" ଏପିସୋଡ୍ ଅର୍ଥ ହେଉଛି ଏକ ସମୟ ଯେତେବେଳେ ପାର୍କିନ୍‌ସନ୍ ରୋଗ ନିମନ୍ତେ ଅନ୍ୟ ଔଷଧଗୁଡିକ ଭଲ କାମ କରୁନଥିବା ଫଳସ୍ୱରୂପ କମ୍ପନ ଏବଂ ଚାଲିବାରେ ଅସୁବିଧା ହୋଇଥାଏ ।^[୩] ଏହା ପାଟିରେ ଦିଆଯାଏ ।^[୩]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଅନିଚ୍ଛାକୃତ ମାଂସପେଶୀ ଗତି, କୋଷ୍ଠକାଠିନ୍ୟ, ହାଲୁସିନେସନ୍, ମୁଣ୍ଡ ବୁଲାଇବା, ବାନ୍ତି, ଏବଂ ଶୋଇବାରେ ଅସୁବିଧା ହୋଇପାରେ ।^[୩] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ବାଧ୍ୟତାମୂଳକ ଆଚରଣ (compulsive behavior) ଅନ୍ତର୍ଭୁକ୍ତ ହୋଇପାରେ | ^[୩] ଏହା ଏକ ଆଡେନୋସିନ ଏ୨ଏ (A2A) ରିସେପ୍ଟର ଆଣ୍ଟାଗୋନିଷ୍ଟ | ^[୫]

୨୦୧୯ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଚିକିତ୍ସା କ୍ଷେତ୍ରରେ ବ୍ୟବହାର ପାଇଁ ଇଷ୍ଟ୍ରାଡେଫାଇଲିନ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୬] ୟୁରୋପରେ ଲାଭ ବିଷୟରେ ଅସ୍ପଷ୍ଟ ପ୍ରମାଣ ହେତୁ ୨୦୨୧ରେ ଅନୁମୋଦନ ମନା କରାଯାଇଥିଲା ।^[୫] ଯୁକ୍ତରାଜ୍ୟରେ ଏହା ଉପଲବ୍ଧ ନୁହେଁ | ^[୧] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହା ପିଛା ମାସକୁ ପ୍ରାୟ ୧୫୦୦ ଡଲାର ଖର୍ଚ୍ଚ ହୋଇଥାଏ ।^[୭]

ଆଧାର

↑ ^୧.୦ ^୧.୧ "Istradefylline". SPS - Specialist Pharmacy Service. 18 September 2019. Archived from the original on 24 May 2021. Retrieved 1 December 2021.
↑ "Nourianz- istradefylline tablet, film coated". DailyMed. Archived from the original on 2 November 2021. Retrieved 4 January 2021.
↑ ^୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ ^୩.୪ "Drug Trials Snapshots: Nourianz". U.S. Food and Drug Administration (FDA). 23 September 2019. Archived from the original on 20 November 2019. Retrieved 19 November 2019.
↑ Cabreira V, Soares-da-Silva P, Massano J (April 2019). "Contemporary Options for the Management of Motor Complications in Parkinson's Disease: Updated Clinical Review". Drugs. 79 (6): 593–608. doi:10.1007/s40265-019-01098-w. PMID 30905034.
↑ ^୫.୦ ^୫.୧ "Nouryant". Archived from the original on 14 November 2021. Retrieved 1 December 2021.
↑ "Istradefylline Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 18 October 2019. Retrieved 26 November 2021.
↑ "Istradefylline Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 1 December 2021.

[SP2021-1] ୧.୦ ^୧.୧ "Istradefylline". SPS - Specialist Pharmacy Service. 18 September 2019. Archived from the original on 24 May 2021. Retrieved 1 December 2021.

[2] "Nourianz- istradefylline tablet, film coated". DailyMed. Archived from the original on 2 November 2021. Retrieved 4 January 2021.

[Snap2021-3] ୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ ^୩.୪ "Drug Trials Snapshots: Nourianz". U.S. Food and Drug Administration (FDA). 23 September 2019. Archived from the original on 20 November 2019. Retrieved 19 November 2019.

[4] Cabreira V, Soares-da-Silva P, Massano J (April 2019). "Contemporary Options for the Management of Motor Complications in Parkinson's Disease: Updated Clinical Review". Drugs. 79 (6): 593–608. doi:10.1007/s40265-019-01098-w. PMID 30905034.

[EPAR2021-5] ୫.୦ ^୫.୧ "Nouryant". Archived from the original on 14 November 2021. Retrieved 1 December 2021.

[AHFS2021-6] "Istradefylline Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 18 October 2019. Retrieved 26 November 2021.

[7] "Istradefylline Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 1 December 2021.

[୩]

[୪]

[୧]

[୨]

[୫]

[୬]

[୭]

Clinical data

Trade names	Nourianz, Nouryant^[୧]
Synonyms	KW-6002
AHFS/Drugs.com	monograph
data	US DailyMed: Istradefylline
Routes of administration	By mouth
Legal status
Legal status	US: ℞-only ^[୨]
Pharmacokinetic data
Protein binding	98%
Metabolism	Mainly CYP1A1, CYP3A4, and CYP3A5
Elimination half-life	64–69 hrs
Excretion	68% faeces, 18% urine
Identifiers
IUPAC name 8-[(E)-2-(3,4-dimethoxyphenyl)vinyl]-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione
ECHA InfoCard	100.230.117
Chemical and physical data
Formula	C₂₀H₂₄N₄O₄
Molar mass	୩୮୪.୪୪ g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES O=C2N(c1nc(n(c1C(=O)N2CC)C)\C=C\c3ccc(OC)c(OC)c3)CC
InChI InChI=1S/C20H24N4O4/c1-6-23-18-17(19(25)24(7-2)20(23)26)22(3)16(21-18)11-9-13-8-10-14(27-4)15(12-13)28-5/h8-12H,6-7H2,1-5H3/b11-9+^Y Key:IQVRBWUUXZMOPW-PKNBQFBNSA-N^Y
(verify)